Furthermore, many cancer studies have shown that such TP53-targeting, gain-of-function (GOF) mutations contribute to resistance of cells to radiation and chemotherapeutic drugs such as cisplatin, doxorubicin, etoposide, and 5-FU [17–20]. Here, TP53 is linked to cancer.